Table 1.
Baseline characteristics between 2008–2011 and 2012–2016.
| a. All Patients | b. Long-Term Survivors a | |||||
|---|---|---|---|---|---|---|
| Variable | 2008–2011 | 2012–2016 | p Value b | 2008–2011 | 2012–2016 | p Value b |
| Total number of patients | 552 | 1202 | 70 (13) | 313 (26) | <0.0001 | |
| Emigrated (%) | 3 (<1) | 2 (<1) | 0 | 0 | ||
| Age | <0.0001 | 0.0007 | ||||
| <70 years | 410 (74) | 739 (62) | 60 (86) | 203 (65) | ||
| ≥70 years | 141 (26) | 463 (39) | 10 (14) | 110 (35) | ||
| Male gender (%) | 336 (61) | 687 (57) | 0.1428 | 36 (51) | 116 (55) | 0.659 |
| Melanoma type | 0.1443 | 0.1267 | ||||
| Cutaneous | 420 (76) | 928 (77) | 59 (84) | 257 (82) | ||
| Mucosal | 18 (3) | 52 (4) | 0 (0) | 15 (5) | ||
| Ocular | 30 (6) | 81 (7) | 0 (0) | 6 (2) | ||
| Unknown primary | 82 (15) | 139 (12) | 11 (16) | 35 (11) | ||
| NA | 2 | 2 | 0 | 0 | ||
| PS (%) | <0.0001 | 0.9151 | ||||
| 0–1 | 275 (92) | 325 (76) | 61 (98) | 71 (99) | ||
| 2–3 | 25 (8) | 102 (24) | 1 (2) | 1 (1) | ||
| NA | 252 | 775 | 8 | 241 | ||
| BRAF status (%) | c | c | ||||
| Wildtype | 546 (50) | 162 (53) | ||||
| Any mutation | 551 (50) | 142 (47) | ||||
| NA | 105 | 8 | ||||
| LDH (%) | 0.0243 | 0.736 | ||||
| Below ULN | 153 (54) | 431 (46) | 38 (63) | 187 (66) | ||
| Above ULN | 133 (47) | 508 (54) | 22 (37) | 94 (34) | ||
| NA | 266 | 263 | 10 | 28 | ||
| Stage (%) | 0.2682 | 0.9146 | ||||
| M1a | 65 (12) | 173 (15) | 20 (29) | 89 (29) | ||
| M1b | 81 (15) | 145 (12) | 16 (23) | 59 (19) | ||
| M1c | 294 (54) | 624 (53) | 29 (41) | 134 (44) | ||
| M1d | 107 (20) | 226 (19) | 5 (7) | 25 (8) | ||
| NA | 5 | 34 | 0 | 5 | ||
| Metastatic sites | ||||||
| CNS (%) | 107 (20) | 226 (19) | 0.7312 | 5 (7) | 25 (8) | 0.8121 |
| NA | 5 | 4 | 0 | 0 | ||
| Bone (%) | 120 (22) | 293 (25) | 0.1278 | 11 (16) | 41 (13) | 0.6055 |
| NA | 5 | 45 | 0 | 6 | ||
| Liver (%) | 216 (40) | 388 (34) | 0.0165 | 10 (14) | 61 (20) | 0.2809 |
| NA | 5 | 45 | 0 | 6 | ||
| Lung (%) | 299 (55) | 580 (50) | 0.0805 | 28 (40) | 135 (44) | 0.5448 |
| NA | 5 | 45 | 0 | 6 | ||
| First line treatment (%) | <0.0001 | <0.0001 | ||||
| IL2/IFN | 283 (51) | 138 (12) | 61 (87) | 40 (13) | ||
| Chemotherapy | 255 (46) | 241 (20) | 7 (10) | 11 (4) | ||
| Anti-PD1 | 0 (0) | 252 (21) | 0 (0) | 111 (36) | ||
| Anti-CTLA-4 | 7 (1) | 306 (26) | 1 (1) | 116 (37) | ||
| BRAFi/MEKi | 4 (1) | 239 (20) | 1 (1) | 22 (7) | ||
| ICI (blinded) | 0 | 3 (<1) | 0 (0) | 2 (1) | ||
| Dabratram/Trametinib/Pembrolizumab | 0 | 5 (<1) | 0 (0) | 4 (1) | ||
| Ipilimumab/Nivolumab | 0 (0) | 15 (1) | 0 (0) | 6 (2) | ||
| Other d | 3 (1) | 3 (<1) | 0 (0) | 1 (<1) | ||
| Anti-CTLA-4 during 1.-7. line of therapy | <0.0001 | 0.4287 | ||||
| Yes | 131 (24) | 561 (47) | 39 (57) | 193 (62) | ||
| No | 419 (76) | 639 (53) | 30 (44) | 120 (38) | ||
| NA | 2 | 3 | 1 | 0 | ||
| Anti-PD1 during 1.-7. line of therapy | <0.0001 | <0.0001 | ||||
| Yes | 18 (3) | 529 (44) | 16 (24) | 241 (77) | ||
| No | 529 (97) | 669 (56) | 52 (77) | 72 (23) | ||
| NA | 5 | 4 | 2 | 0 | ||
| BRAFi/MEKi during 1.-7. line of therapy | <0.0001 | 0.5326 | ||||
| Yes | 46 (8) | 434 (36) | 19 (28) | 75 (24) | ||
| No | 503 (92) | 767 (64) | 50 (73) | 238 (76) | ||
| NA | 3 | 1 | 1 | 0 | ||
| Any anti-CTLA-4 or anti-PD1 during 1.-7. line of therapy | <0.0001 | <0.0001 | ||||
| Yes | 133 (24) | 790 (66) | 41 (59) | 290 (93) | ||
| No | 417 (76) | 411 (34) | 28 (41) | 23 (7) | ||
| NA | 2 | 1 | 1 | 0 | ||
| Best objective response (%) | <0.0001 | 0.5224 | ||||
| CR | 23 (8) | 105 (11) | 22 (35) | 97 (33) | ||
| PR | 47 (16) | 242 (26) | 18 (29) | 81 (28) | ||
| SD | 108 (36) | 237 (25) | 17 (27) | 66 (23) | ||
| PD | 126 (41) | 365 (39) | 6 (10) | 49 (17) | ||
| NA | 248 | 253 | 7 | 20 | ||
| Treatment lines received (%) | 0.0004 | 0.0054 | ||||
| 1 | 552 (100) | 1202 (100) | 70 (100) | 313 (100) | ||
| 2 | 206 (37) | 614 (51) | 47 (67) | 193 (62) | ||
| 3 | 79 (14) | 281 (23) | 32 (46) | 96 (31) | ||
| 4 | 30 (5) | 109 (9) | 21 (30) | 46 (15) | ||
| 5 | 20 (4) | 47 (4) | 19 (27) | 29 (9) | ||
| 6 | 5 (1) | 16 (1) | 5 (7) | 12 (4) | ||
| 7 | 0 (0) | 4 (<1) | 0 (0) | 4 (1) | ||
a Overall survival above 3 years; b chi-square-test; c analysis of BRAF mutation status was not performed; d dendritic cell vaccination, T cell therapy, intralesional IL2; PS = performance status; NA = not applicable; IL2/IFN = interleukin-2/interferon-alpha; ICI = immune checkpoint-inhibitor; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; ULN = upper level of normal.